With the steady growth of China's economy and the improvement of residents' health awareness, the public's demand for high-quality medical services is increasing, which has brought huge market demand to China's medical apparatus industry. At present, the domestic medical apparatus industry in our country is developing steadily. According to the data of the National Bureau of Statistics, from 2005 to 2022, its market size increased from 60 billion yuan to more than 900 billion yuan, and the annual growth rate exceeded the global average. Roland Berger's "China's medical apparatus industry development status and trends" report shows that the size of China's medical apparatus market will reach 958.20 billion yuan (RMB) in 2022, with a compound growth rate of about 17.5% in the past seven years, which has jumped to the second largest market in the world except the United States. At the same time, the current drug-to-device ratio in our country is only 2.9. The low per capita device expenditure and clinical penetration rate show that China's medical apparatus industry is full of development potential in the future.
On July 24, the policy was up the ante again. The National Development and Reform Commission and the Ministry of Finance issued the "Several Measures on Afterburner Support for Large-scale Equipment Update and Trade-in of Consumer Goods" (hereinafter referred to as the "Measures"), proposing to make overall arrangements of about 300 billion yuan for ultra-long-term special treasury bonds. Afterburner supports large-scale equipment renewal and trade-in of consumer goods. The NDRC said: "About 150 billion yuan to support the trade-in of local consumer goods and the first batch of about 50 billion yuan to support the renewal of equipment will be issued in the near future. At the same time, a new batch of equipment renewal projects will be organized for application review, and it is planned that by the end of August, all funds of about 300 billion yuan will be issued."
According to Frost & Sullivan's latest report, the global medical apparatus market will reach $623 billion in 2024, and China will grow faster, becoming the fastest growing market in Asia at 941.70 billion yuan. However, China's medical apparatus industry competition is fierce, according to the drug intelligence medical equipment data - production enterprise database statistics, the current Chinese medical apparatus production enterprise license/record number reached 45,657, the number of enterprises is large but the scale is small, the industry concentration is low. In addition, the medical apparatus category is complex, product homogeneity is serious, coupled with the growth of market demand and the promotion of policies such as medical insurance control fees and centralized procurement, which makes product prices under pressure, forcing the industry to explore new growth space and accelerate innovative Product Research & Development.
On June 20, the State Food and Drug Administration reviewed and approved the measures on optimizing the whole life cycle supervision to support the innovation and development of high-end medical apparatus, and proposed ten specific measures to support the major innovation of high-end medical apparatus and promote the application of more new technologies, new materials, new processes and new methods in the field of medical health. As an important part of the big health industry, the medical apparatus industry is currently in a critical transition period from low-end manufacturing to high value-added products, and high-end, intelligent and internationalization have become the main line of industry development.
According to the official website of the State Drug Administration, in order to implement the relevant work arrangements of the General Office of the State Council on comprehensively deepening the supervision reform of pharmaceutical medical apparatus and promoting the high-quality development of the pharmaceutical industry, support the export trade of medical apparatus products, and standardize the handling of service matters issued by the drug supervision and administration department for the export sales certificate of medical apparatus, the State Food and Drug Administration has organized and drafted the "Regulations on the Administration of Medical Apparatus Export Sales Certificates (Revised Draft exposure draft) ", which is now open to the public for comments.
In front of the exhibition area of the Digital Intelligence Brain Health Base, the display of cerebrovascular interventional surgery robots attracted everyone's attention. According to Shi Wenbao, the head of the exhibition manufacturer Beijing Wansi Medical Apparatus Co., Ltd., in order to avoid radiation, the traditional neurointerventional cerebrovascular angiography requires the healthcare workers to wear heavy lead clothes and lead scarves. After the surgical robot came out, the healthcare workers only need to sit at the operating table outside the operating room and control the robotic arm in the operating room through the operating handle to complete the operation, realizing the implementation of "zero" radiation surgery, which solves the clinical pain points of radiation injury of vascular interventional doctors for a long time. " At this conference, Fengtai District launched two key projects in the field of brain science and high-end medical apparatus, which is very attractive for the incubation of our innovative medical apparatus, which can help us solve the clinical needs of products from the source and realize the closed loop of the industrial chain from clinical to clinical. "Shi Wenbao said.
Medical apparatus is an important part of the above-mentioned trade-in plan. In the implementation of equipment renewal action part, the trade-in plan points out that strengthen the construction of high-quality and efficient medical and health service system, promote the iterative upgrade of medical and health institutions equipment and information facilities, and encourage qualified medical institutions to speed up the update and transformation of medical equipment such as medical imaging, radiation therapy, remote diagnosis and treatment, and surgical robots. Promote the transformation and improvement of medical institutions' wards to make up for the shortcomings of ward environment and facilities.
Suzhou and Wuhan are the only non-first-tier cities to rank in the top ten in all aspects. On the one hand, Suzhou has actively undertaken the spillover effect of R & D from first-tier cities, and at the same time, it has fully cultivated in vertical fields such as nanomaterials and medical robots, completing the transformation from undertaking supporting facilities to leading in sub-segments. Wuhan relies on its technological and innovative advantages in the biological field, combined with its own manufacturing heritage, to attract leading companies such as Mindray Bio and United Imaging Medical.